The Missing Triage Step in AI Antibody Hit Validation

AI models are generating thousands of promising antibody variants faster than ever before. But because downstream mammalian expression and SPR validation are high-cost and time-consuming, teams are forced into a costly bottleneck—often over-investing in candidates that simply do not bind.

Join Sumit Kalsi, Associate Director of Product Research at Nuclera, for insights into the exclusive launch of Nuclera’s Rapid Antibody Screening Service. Discover how integrating a rapid, 96-plex cell-free binary expression and binding screen can act as the ultimate early filter for your pipeline.

Sumit will walk through the frictionless journey—from digital sequences to decision-grade data—and share validation data proving that cell-free produced IgG1 antibodies perfectly reproduce CHO binding profiles. Stop burning budget on non-binders and learn how to reserve your expensive mammalian scale-up exclusively for winning candidates.